Search Within

Jose T Baselga

  1. "Pedram Razavi"
Formats
  1. Journal Article (17)
  2. Meeting Abstract (13)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (31)
  2. Department of Medicine (31)
  3. Hematology-Oncology Fellows (31)
  4. Solid Tumor Oncology Division (31)
  5. Weinberg Fellows (31)
  6. GSK Faculty (28)

More Groups

People
  1. Pedram Razavi (31)
  2. Michael Berger (17)
  3. Sarat Chandarlapaty (17)
  4. Ahmet Zehir (14)
  5. Dara Ross (13)
  6. David Hyman (12)

More People

Years
  1. 2021 (2)
  2. 2020 (5)
  3. 2019 (5)
  4. 2018 (6)
  5. 2017 (6)
  6. 2016 (6)

More Years

Publications
  1. Cancer Cell (4)
  2. Cancer Research (4)
  3. Modern Pathology (4)
  4. Cancer Discovery (3)
  5. Journal of Clinical Oncology (3)
  6. Nature Genetics (3)

More Publications

Publishers
  1. American Association for Cancer Research (8)
  2. Nature Publishing Group (7)
  3. American Society of Clinical Oncology (4)
  4. Cell Press (4)
  5. Nature Research (4)
  6. American Association for the Advancement of Science (2)

More Publishers

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of CDH1 in invasive lobular carcinoma (ILC): Comparison of morphology, immunohistochemistry (IHC) and mutation profile detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Grabenstetter, A.; Mohanty, A. S.; Zehir, A.; Razavi, P.; Baselga, J.; Tan, L. K.; Ross, D. S.
    Modern Pathology (2017)

    Fulltext@MSK | Save
  • Analysis of CDH1 in invasive lobular carcinoma (ILC): Comparison of morphology, immunohistochemistry (IHC) and mutation profile detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Grabenstetter, A.; Mohanty, A. S.; Zehir, A.; Razavi, P.; Baselga, J.; Tan, L. K.; Ross, D. S.
    Laboratory Investigation (2017)

    Fulltext@MSK | Save
  • Activating ESR1 mutations differentially affect the efficacy of ER antagonists
    Journal Article

    Toy, W.; Weir, H.; Razavi, P.; Lawson, M.; Goeppert, A. U.; Mazzola, A. M.; Smith, A.; Wilson, J.; Morrow, C.; Wong, W. L.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay
    Journal Article

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Systematic functional characterization of resistance to PI3K inhibition in breast cancer
    Journal Article

    Le, X.; Antony, R.; Razavi, P.; Treacy, D. J.; Luo, F.; Ghandi, M.; Castel, P.; Scaltriti, M.; Baselga, J.; Garraway, L. A.
    Cancer Discovery (2016)

    Fulltext@MSK | Save
  • PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition
    Journal Article

    Castel, P.; Ellis, H.; Bago, R.; Toska, E.; Razavi, P.; Carmona, F. J.; Kannan, S.; Verma, C. S.; Dickler, M.; Chandarlapaty, S.; more...
    Cancer Cell (2016)

    Fulltext@MSK | Save
  • Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
    Meeting Abstract

    Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save